- KALA BIO (KALA, Financial) to host a virtual KOL event on July 16, 2025, at 4:00 p.m. ET to discuss KPI-012 for treating PCED.
- Distinguished ophthalmology experts to present insights into KPI-012's clinical trials and commercial potential.
- The event will include a Q&A session and will be available for replay on the company's website.
KALA BIO, Inc. (KALA), a clinical-stage biopharmaceutical company, is set to host a virtual Key Opinion Leader (KOL) event on July 16, 2025, at 4:00 p.m. ET. The event will focus on KPI-012, an investigational treatment aimed at addressing persistent corneal epithelial defect (PCED), a rare ocular disease.
Esteemed speakers, including Dr. Francis Mah from Scripps Clinic, Dr. Anthony Aldave from Jules Stein Eye Institute, Dr. Stephen Pflugfelder from Baylor College of Medicine, and Dr. Melissa Toyos from Toyos Clinic, will provide an overview of PCED, discuss unmet patient needs, and elaborate on the results from the CHASE clinical trial.
Interim CEO Todd Bazemore will discuss the commercial potential of KPI-012 and outline upcoming milestones for KALA BIO. This presentation will be followed by a Q&A session. Interested parties can attend the live webcast by registering through KALA's website, where an archived replay will also be available after the event.
KALA BIO is recognized for its dedication to developing novel therapies for rare and severe ocular conditions, utilizing their proprietary mesenchymal stem cell secretome (MSC-S) platform. KPI-012 has garnered both Orphan Drug and Fast Track designations from the U.S. FDA, further reflecting its potential impact on unmet medical needs in ophthalmology.
